Intravenous DNase I: Dose-escalating intravenous infusion of DNase I
Study summary
Phase I dose-escalation safety and feasibility of IV DNase I in ICU septic patients.
Eligibility
Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria:
1. Age of ≥18 years
2. Admitted to the ICU in the last 48 hours
3. Suspected or proven infection as the admitting diagnosis
4. A sequential (sepsis) organ function assessment (SOFA) score of ≥2 above baseline
5. Expected to remain in the ICU for ≥ 72 hours
Exclusion Criteria:
1. No consent/inability to obtain consent from a substitute decision-maker
2. Have other forms of clinically apparent shock, including cardiogenic, obstructive (massive pulmonary embolism, cardiac tamponade, tension pneumothorax), hemorrhagic, neurogenic, or anaphylactic shock
3. Have a significant risk of bleeding as evidenced by one of the following:
* Surgery requiring general or spinal anesthesia within 24 hours before enrolment
* The potential need for surgery in the next 24 hours
* Evidence of active bleeding
* A history of severe head trauma requiring hospitalization
* Intracranial surgery, or stroke within three months before the study
* Any history of intracerebral arteriovenous malformation, cerebral aneurysm, or mass lesions of the central nervous system
* A history of congenital bleeding diatheses
* Gastrointestinal bleeding within five weeks before the study unless corrective surgery had been performed
* Trauma is considered to increase the risk of bleeding
* Presence of an epidural catheter
* Need for therapeutic anticoagulation
4. Receiving DNase I by inhalation
5. Terminal illness with a life expectancy of fewer than three months
6. Pregnant and/or breastfeeding
Primary outcome measure(s)
Number of patients recruited per month from the start of the study — up to 24 months Number of patients recruited per month
Number of patients who completed the protocol — up to 7 days The ability to complete study infusion and blood collection as prescribed
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.